Royalty Pharma holder plans $5.8M share sale

Royalty Pharma plc (RPRX) received a notice that SCH Investment Partners LLC intends to sell 100,000 Class A Ordinary Shares under Rule 144 through Merrill Lynch.

Rhea-AI Filing Summary

Royalty Pharma plc (RPRX) received a notice that SCH Investment Partners LLC intends to sell 100,000 Class A Ordinary Shares under Rule 144 through Merrill Lynch. The proposed sale has an approximate aggregate market value of $5,846,972.43, compared with 445,277,344 Class A Ordinary Shares outstanding. SCH Investment Partners LLC previously sold 350,000 Class A Ordinary Shares during the past three months under a Rule 10b5-1(c) selling plan dated March 20, 2026.

Key Figures

Shares proposed to be sold: 100,000 Class A Ordinary Shares Proposed sale aggregate market value: $5,846,972.43 Shares outstanding: 445,277,344 Class A Ordinary Shares +5 more

8 metrics

Shares proposed to be sold 100,000 Class A Ordinary Shares Planned Rule 144 sale by SCH Investment Partners LLC

Proposed sale aggregate market value $5,846,972.43 Approximate market value of 100,000 Class A Ordinary Shares to be sold

Shares outstanding 445,277,344 Class A Ordinary Shares Royalty Pharma plc Class A Ordinary Shares outstanding as cited in the notice

Recent sale June 23, 2026 150,000 shares for $8,166,766.13 SCH Investment Partners LLC sale of Class A Ordinary Shares

Recent sale June 30, 2026 100,000 shares for $5,645,700.97 SCH Investment Partners LLC sale of Class A Ordinary Shares

Recent sale August 18, 2026 100,000 shares for $5,991,122.91 SCH Investment Partners LLC sale of Class A Ordinary Shares

Rule 10b5-1 selling plan date March 20, 2026 Date of selling plan covering the disclosed sales

Acquisition date of shares to be sold May 13, 2024 Shares acquired from issuer in private transaction

Key Terms

Rule 144, Rule 10b5-1(c), selling plan, Class A Ordinary Shares, +1 more

5 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Rule 10b5-1(c) regulatory

"selling plan dated 03/20/2026, which is intended to comply with Rule 10b5-1(c)."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

selling plan financial

"sales of shares set forth herein are made in connection with a selling plan dated 03/20/2026"

Class A Ordinary Shares financial

"Class A Ordinary Shares | Merrill Lynch One Byrant Park New York NY 10036 | 100000"

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

private transaction financial

"Acquired from issuer in private transaction"

A private transaction is the sale or transfer of securities, assets, or ownership stakes carried out directly between a small number of parties rather than on a public exchange. For investors it matters because these deals are less visible and often less liquid than public trades, so pricing can be harder to verify, the investment can be harder to sell quickly, and buyers or sellers may gain strategic advantages not available in open markets — like negotiated terms similar to a private garage sale versus a crowded marketplace.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Royalty Pharma plc (RPRX)?

The filing discloses that SCH Investment Partners LLC intends to sell 100,000 Class A Ordinary Shares of Royalty Pharma plc under Rule 144, with an approximate aggregate market value of $5,846,972.43, using Merrill Lynch as broker.

How many Royalty Pharma plc (RPRX) shares has SCH Investment Partners LLC sold recently?

SCH Investment Partners LLC reported sales of 350,000 Class A Ordinary Shares in the past three months: 150,000 shares on June 23, 2026; 100,000 shares on June 30, 2026; and 100,000 shares on August 18, 2026.

What were the dollar amounts of the recent RPRX share sales by SCH Investment Partners LLC?

The reported sales were for $8,166,766.13 on June 23, 2026; $5,645,700.97 on June 30, 2026; and $5,991,122.91 on August 18, 2026, all involving Class A Ordinary Shares of Royalty Pharma plc.

What is the total number of Royalty Pharma plc Class A Ordinary Shares outstanding cited in the filing?

The notice cites 445,277,344 Class A Ordinary Shares of Royalty Pharma plc as outstanding, providing context for the size of the planned Rule 144 sale by SCH Investment Partners LLC.

Is the planned sale of RPRX shares under a Rule 10b5-1 trading plan?

Yes. The filing states that the sales of shares are made in connection with a selling plan dated March 20, 2026, which is intended to comply with Rule 10b5-1(c).

When were the 100,000 RPRX shares to be sold originally acquired and from whom?

The 100,000 Class A Ordinary Shares covered by the notice were acquired from the issuer in a private transaction on May 13, 2024.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/22/2026 - 04:51 PM Accepted by SEC EDGAR 09/22/2026 - 04:50 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002094176
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Royalty Pharma PLC
SEC File Number	001-39329
Address of Issuer	110 East 59th Street New York NEW YORK 10022
Phone	212-883-0200
Name of Person for Whose Account the Securities are To Be Sold	SCH Investment Partners LLC
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Ordinary Shares	Merrill Lynch One Byrant Park New York NY 10036	100000	5846972.43	445277344	09/22/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Ordinary Shares	05/13/2024	Acquired from issuer in private transaction	Issuer			100000	05/13/2024	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
SCH Investment Partners LLC 110 E 59th Street New York NY 10022	Class A Ordinary Shares	06/23/2026	150000	8166766.13
SCH Investment Partners LLC 110 E 59th Street New York NY 10022	Class A Ordinary Shares	06/30/2026	100000	5645700.97
SCH Investment Partners LLC 110 E 59th Street New York NY 10022	Class A Ordinary Shares	08/18/2026	100000	5991122.91

144: Remarks and Signature

Remarks	The sales of shares set forth herein are made in connection with a selling plan dated 03/20/2026, which is intended to comply with Rule 10b5-1(c).
Date of Notice	09/22/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/20/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Christopher Hite
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)